Fennec Pharmaceuticals 관리

관리 기준 확인 2/4

Fennec Pharmaceuticals CEO는 Rosty Raykov, Jul2009 에 임명되었습니다 의 임기는 15.33 년입니다. 총 연간 보상은 $ 2.54M, 23.9% 로 구성됩니다. 23.9% 급여 및 76.1% 보너스(회사 주식 및 옵션 포함). 는 $ 268.06K 가치에 해당하는 회사 주식의 0.24% 직접 소유합니다. 268.06K. 경영진과 이사회의 평균 재임 기간은 각각 4.5 년과 10.6 년입니다.

주요 정보

Rosty Raykov

최고 경영자

US$2.5m

총 보상

CEO 급여 비율	23.9%
CEO 임기	15.3yrs
CEO 소유권	0.2%
경영진 평균 재임 기간	4.5yrs
이사회 평균 재임 기간	10.6yrs

최근 관리 업데이트

Recent updates

Revenues Working Against Fennec Pharmaceuticals Inc.'s (NASDAQ:FENC) Share Price

Oct 04

Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Analysts Are More Bearish Than They Used To Be

Aug 15

Is Fennec Pharmaceuticals (NASDAQ:FENC) A Risky Investment?

Jul 16

Lacklustre Performance Is Driving Fennec Pharmaceuticals Inc.'s (NASDAQ:FENC) 27% Price Drop

Jun 02

Risks To Shareholder Returns Are Elevated At These Prices For Fennec Pharmaceuticals Inc. (NASDAQ:FENC)

Apr 18

Earnings Update: Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Just Reported And Analysts Are Boosting Their Estimates

Nov 09

Fennec wins FDA approval of Pedmark for chemotherapy-induced ototoxicity in children

Sep 20

Buying Fennec Pharma Ahead Of September PDUFA For Pedmark

Aug 23

Fennec Pharmaceuticals secures up to $45M financing facility from Petrichor

Aug 01

Fennec Pharmaceuticals: Will Pedmark Make It To Market At Second Time Of Asking?

Oct 29

Fennec Pharmaceuticals (NASDAQ:FENC) Is In A Good Position To Deliver On Growth Plans

May 26

Breakeven On The Horizon For Fennec Pharmaceuticals Inc. (NASDAQ:FENC)

Apr 01

Do Institutions Own Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Shares?

Mar 02

CEO 보상 분석

Rosty Raykov 의 보수는 Fennec Pharmaceuticals 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Sep 30 2024	n/a	n/a	-US$1m
Jun 30 2024	n/a	n/a	US$3m
Mar 31 2024	n/a	n/a	US$3m
Dec 31 2023	US$3m	US$607k	-US$16m
Sep 30 2023	n/a	n/a	-US$20m
Jun 30 2023	n/a	n/a	-US$26m
Mar 31 2023	n/a	n/a	-US$26m
Dec 31 2022	US$614k	US$503k	-US$24m
Sep 30 2022	n/a	n/a	-US$21m
Jun 30 2022	n/a	n/a	-US$17m
Mar 31 2022	n/a	n/a	-US$16m
Dec 31 2021	US$3m	US$468k	-US$17m
Sep 30 2021	n/a	n/a	-US$16m
Jun 30 2021	n/a	n/a	-US$18m
Mar 31 2021	n/a	n/a	-US$19m
Dec 31 2020	US$2m	US$430k	-US$18m
Sep 30 2020	n/a	n/a	-US$18m
Jun 30 2020	n/a	n/a	-US$14m
Mar 31 2020	n/a	n/a	-US$14m
Dec 31 2019	US$1m	US$489k	-US$13m
Sep 30 2019	n/a	n/a	-US$12m
Jun 30 2019	n/a	n/a	-US$13m
Mar 31 2019	n/a	n/a	-US$11m
Dec 31 2018	US$1m	US$350k	-US$10m
Sep 30 2018	n/a	n/a	-US$9m
Jun 30 2018	n/a	n/a	-US$9m
Mar 31 2018	n/a	n/a	-US$8m
Dec 31 2017	US$450k	US$263k	-US$7m

보상 대 시장: Rosty 의 총 보상 ($USD 2.54M )은 US 시장( $USD 651.15K ).

보상과 수익: 회사가 수익성이 없는 동안 Rosty 의 보상이 증가했습니다.

CEO

Rosty Raykov (48 yo)

15.3yrs

테뉴어

US$2,540,940

보상

Mr. Rostislav Raykov, also known as Rosty, has been the Chief Executive Officer of c Pharmaceuticals Inc. since July 2009. Mr. Raykov is an Independent Director of Lavras Gold Corp. since April 1, 2022. Mr...

리더십 팀

이름	위치	테뉴어	보상	소유권
Rostislav Raykov	CEO & Director	15.3yrs	US$2.54m	0.24% $ 268.1k
Robert Andrade	Chief Financial Officer	9yrs	US$1.31m	0.41% $ 450.2k
Terry Evans	Chief Commercial Officer	less than a year	데이터 없음	데이터 없음
Pierre Sayad	Chief Medical Officer	less than a year	데이터 없음	데이터 없음
Christiana Cioffi	Chief Strategy Officer	less than a year	데이터 없음	데이터 없음
Mark Gowland	Controller	9yrs	데이터 없음	데이터 없음
Lei Fang	President of Pharstat Inc	no data	데이터 없음	데이터 없음

4.5yrs

평균 재임 기간

경험이 풍부한 관리: FENC 의 관리팀은 경험 ( 4.5 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Rostislav Raykov	CEO & Director	15.3yrs	US$2.54m	0.24% $ 268.1k
Chris Rallis	Independent Director	13.3yrs	US$173.18k	0.18% $ 196.2k
Khalid Islam	Independent Chairman of the Board	10.6yrs	US$225.23k	0.78% $ 862.8k
Jodi Cook	Independent Director	5.2yrs	US$153.81k	0% $ 0
Marco Brughera	Independent Director	8.3yrs	US$166.31k	0% $ 0

10.6yrs

평균 재임 기간

69yo

평균 연령

경험이 풍부한 이사회: FENC 의 이사회는 노련하고 경험이 있습니다(평균 재직 기간 10.6 년).

Fennec Pharmaceuticals 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Fennec Pharmaceuticals Inc. Announces Management Appointments

Fennec Pharmaceuticals Inc. Announces CEO Changes

Fennec Pharmaceuticals Inc. Announces Executive Changes

Chief Operating Officer recently sold US$414k worth of stock

Chief Operating Officer recently sold US$228k worth of stock

Fennec Pharmaceuticals Inc., Annual General Meeting, Jun 25, 2024

Recent updates

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Fennec Pharmaceuticals Inc. to Report Q3, 2024 Results on Nov 07, 2024

Fennec Pharmaceuticals Inc. Announces Management Appointments

Revenues Working Against Fennec Pharmaceuticals Inc.'s (NASDAQ:FENC) Share Price

Price target decreased by 7.9% to US$15.50

Consensus revenue estimates fall by 14%

Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Analysts Are More Bearish Than They Used To Be

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Fennec Pharmaceuticals Inc. to Report Q2, 2024 Results on Aug 13, 2024

Consensus EPS estimates increase by 18%

Fennec Pharmaceuticals Inc. Announces CEO Changes

New minor risk - Share price stability

Is Fennec Pharmaceuticals (NASDAQ:FENC) A Risky Investment?

Fennec Pharmaceuticals Inc. Announces Executive Changes

Lacklustre Performance Is Driving Fennec Pharmaceuticals Inc.'s (NASDAQ:FENC) 27% Price Drop

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Chief Operating Officer recently sold US$414k worth of stock

Risks To Shareholder Returns Are Elevated At These Prices For Fennec Pharmaceuticals Inc. (NASDAQ:FENC)

Chief Operating Officer recently sold US$228k worth of stock

Fennec Pharmaceuticals Inc., Annual General Meeting, Jun 25, 2024

CEO & Director notifies of intention to sell stock

Price target increased by 11% to US$18.17

Chief Financial Officer notifies of intention to sell stock

Fennec Pharmaceuticals Inc. Provides Unaudited Earnings Guidance for the Fourth Quarter and Full Year of 2023

Fennec Pharmaceuticals Inc. Announces U.S. Food and Drug Administration Issues Reminder of Non-Substitution of PEDMARK®? (Sodium Thiosulfate Injection) for Pediatric Patients Receiving Cisplatin

Chief Financial Officer notifies of intention to sell stock

New minor risk - Shareholder dilution

Independent Chairman of the Board exercised options to buy US$1.8m worth of stock.

Earnings Update: Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Just Reported And Analysts Are Boosting Their Estimates

CEO & Director recently bought US$119k worth of stock

Fennec Pharmaceuticals Inc. to Report Q3, 2023 Results on Nov 06, 2023

New minor risk - Shareholder dilution

New minor risk - Shareholder dilution

Fennec Pharmaceuticals Inc. Announces the Appointment of Adrian Haigh as Chief Operating Officer

Fennec Pharmaceuticals Inc. to Report Q2, 2023 Results on Aug 03, 2023

Independent Director recently sold US$42k worth of stock

Chief Financial Officer notifies of intention to sell stock

Fennec Pharmaceuticals Announces European Commission Marketing Authorization for Pedmarqsi™? (sodium Thiosulfate) to Reduce the Risk of Hearing Loss in Pediatric Oncology Patients

Consensus revenue estimates increase by 10%, EPS downgraded

Fennec Pharmaceuticals Inc. to Report Q1, 2023 Results on May 11, 2023

Fennec Pharmaceuticals Inc. Announces Pedmark® (Sodium Thiosulfate Injection) Receives Orphan Drug Exclusivity from U.S. FDA

Fennec Pharmaceuticals Announces Updated NCCN Clinical Practice Guidelines Recommend PEDMARK® (sodium thiosulfate injection) to Reduce the Risk of Cisplatin-Induced Hearing Loss in Pediatric Patients

CEO & Director recently sold US$276k worth of stock

Insufficient new directors

Insufficient new directors

Fennec Pharmaceuticals Inc. Announces Commercial Availability of PEDMARK(R) (Sodium Thiosulfate Injection) in the United States

Insufficient new directors

Berkshire Sterile Client Fennec Pharmaceuticals Inc. Receives FDA Approval on Product Indicated to Reduce Risk of Hearing Loss for Childhood Cancer Patients

Price target increased to US$12.00

Fennec Pharmaceuticals Inc. Announces FDA Approval of PEDMARK

Fennec wins FDA approval of Pedmark for chemotherapy-induced ototoxicity in children

CEO & Director exercised options to buy US$350k worth of stock.

Buying Fennec Pharma Ahead Of September PDUFA For Pedmark

Fennec Pharmaceuticals Inc. announced that it expects to receive $45 million in funding from Petrichor Healthcare Capital Management LP

Fennec Pharmaceuticals secures up to $45M financing facility from Petrichor

Fennec Pharmaceuticals Inc., Annual General Meeting, Jun 14, 2022

The Law Offices of Vincent Wong Remind Fennec Pharmaceuticals Inc. Investors of A Lead Plaintiff Deadline of April 11, 2022

Pomerantz Law Firm Files Class Action Against Fennec Pharmaceuticals Inc. and Certain of Its Officers

Shubh Goel to Depart Fennec Pharmaceuticals Inc. as Chief Commercial Officer in Late February 2022

Price target decreased to US$10.80

Consensus revenue estimates increase to US$25.0m

Forecast breakeven date moved forward to 2021

Fennec Pharmaceuticals Inc. Expects to Receive Complete Response Letter from the FDA for Its New Drug Application for Pedmark

Fennec Pharmaceuticals: Will Pedmark Make It To Market At Second Time Of Asking?

Forecast breakeven moved forward to 2021

Elion Oncology, Inc. acquired Eniluracil from Fennec Pharmaceuticals, Inc. for $0.04 million.

Fennec Could See Upside If Pedmark Gets Approved

Fennec Pharmaceuticals Inc.(NasdaqCM:FENC) dropped from Russell 3000 Growth Index

Fennec Pharmaceuticals Announces FDA Acceptance of New Drug Application Resubmission for PEDMARK™